PitchBook年一季度制药生物工具风险投资趋势（英）

EMERGING TECH RESEARCHPharma Biotools VC TrendsVC activity across the pharma biotools ecosystemQ12025REPORT PREVIEWThe full report is available through the PitchBook Platform.CONFIDENTIAL. NOT FOR REDISTRIBUTION. PG 2ContentsInstitutional Research GroupAnalysisKazi Helal, Ph.D. Senior Research Analyst, Biotech and Pharma kazi.helal@pitchbook.comDataHarrison Waldock Data Analystpbinstitutionalresearch@pitchbook.comPublishingReport designed by Jenna O’Malley, Chloe Ladwig, and Julia MidkiffPublished on June 3, 2025Q1 2025 Pharma Biotools VC TrendsPharma biotools landscape3Pharma biotools VC ecosystem market map4Pharma biotools VC activity5Pharma biotools VC deal summary17For previous updates as well as our complete biotools research, please see the designated analyst workspace on the PitchBook Platform.CONFIDENTIAL. NOT FOR REDISTRIBUTION. PG 3Q1 2025 Pharma Biotools VC TrendsPharma biotools landscape312Mature modalitiesAdvanced modalitiesEmerging modalities123CONFIDENTIAL. NOT FOR REDISTRIBUTION. PG 5Q1 2025 Pharma Biotools VC TrendsVC activityQuarter highlightsFunding activity sees a strong rebound: Investment in pharma biotools has mirrored that of broader biopharma cycles. After peaking in 2020-2021 at $10.4 billion across 430 deals, funding corrected through 2022-2023 before beginning to resurge in 2024. Q1 2025 demonstrated a strong rebound, recording 65 deals (up 8.3% from Q4 2024) with $1.3 billion in funding. This marked an 81.4% quarterly increase and the highest level of investment since Q2 2024. However, the industry is very consolidated, with fewer but massive deals driven by intellectual property and patents.Investors shift toward higher-value deals: In the trailing 12 months, deal activity declined 9.5% to 238 deals, but total funding increased 12.8% to $4.8 billion, indicating larger average deal sizes and investor focus on more mature opportunities. This trend suggests market stabilization around selective, quality-focused investments while maintaining robust capital deployment.Investment trends and market dynamicsAI and computational biology lead investment focus: AI-driven drug discovery, synthetic biology, and next-generation sequencing remain top targets, with computational biology platforms seeing particularly strong interest. Investors increasingly favor multiapplication platforms over single-product plays, driving consolidation around companies with broad technology applicability.Emerging technology areas gain momentum: Lab automation and computational tools have continued to attract sustained interest, while diagnostic multiomics platforms have gained significant momentum as personalized medicine adoption accelerates. Spatial biology, single-cell analysis tools, and AI-powered laboratory management systems are attracting growing investor attention as the industry pushes toward more integrated, data-driven research environments.Source: PitchBook • Geography: Global • As of March 31, 2025Pharma biotools VC deal acti